Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network.

Blood. 2012 Mar 22;119(12):2746-53. doi: 10.1182/blood-2011-04-344507. Epub 2012 Jan 25.

2.

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.

Ann Hematol. 2013 Jan;92(2):211-9. doi: 10.1007/s00277-012-1588-x. Epub 2012 Oct 21.

3.

Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients.

El Beshlawy A, El Tagui M, Hamdy M, El Ghamrawy M, Azim KA, Salem D, Said F, Samir A, St Pierre T, Pennell DJ.

Ann Hematol. 2014 Mar;93(3):375-9. doi: 10.1007/s00277-013-1876-0. Epub 2013 Aug 15.

PMID:
23949317
4.

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Fischer R, Piga A, Harmatz P, Nielsen P.

Ann N Y Acad Sci. 2005;1054:350-7. Review.

PMID:
16339683
5.

Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E.

Blood Cells Mol Dis. 2013 Feb;50(2):99-104. doi: 10.1016/j.bcmd.2012.10.006. Epub 2012 Nov 11.

7.

Current recommendations for chelation for transfusion-dependent thalassemia.

Kwiatkowski JL.

Ann N Y Acad Sci. 2016 Mar;1368(1):107-14. doi: 10.1111/nyas.13088. Review.

PMID:
27186943
8.

Thalassemia.

Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E.

Hematology Am Soc Hematol Educ Program. 2004:14-34. Review.

PMID:
15561674
9.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.

Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25.

10.

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.

Eur J Haematol. 2017 Feb;98(2):97-105. doi: 10.1111/ejh.12793. Epub 2016 Sep 20.

PMID:
27537786
11.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
12.

Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.

Merchant R, Ahmed J, Krishnan P, Jankharia B.

Indian Pediatr. 2012 Apr;49(4):281-5. Epub 2011 Aug 15.

13.

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A.

Eur J Haematol. 2009 Jun;82(6):458-65. doi: 10.1111/j.1600-0609.2009.01228.x. Epub 2009 Jan 28.

14.

Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.

Chuansumrit A, Pengpis P, Mahachoklertwattana P, Sirachainan N, Poomthavorn P, Sungkarat W, Kadegasem P, Khlairit P, Wongwerawattanakoon P.

Acta Haematol. 2017;137(1):20-26. doi: 10.1159/000450673. Epub 2016 Nov 12.

PMID:
27838686
15.

Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).

Maira D, Cassinerio E, Marcon A, Mancarella M, Fraquelli M, Pedrotti P, Cappellini MD.

Ann Hematol. 2017 Nov;96(11):1931-1936. doi: 10.1007/s00277-017-3120-9. Epub 2017 Sep 5.

PMID:
28875336
16.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD.

Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18.

18.

Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.

Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, Thompson AA, Neufeld EJ, Yamashita R; Thalassemia Clinical Research Network.

Qual Life Res. 2014 Oct;23(8):2277-88. doi: 10.1007/s11136-014-0671-2. Epub 2014 Mar 30.

19.

Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients.

Ooi GC, Khong PL, Chan GC, Chan KN, Chan KL, Lam W, Ng I, Ha SY.

Br J Haematol. 2004 Feb;124(3):385-90.

PMID:
14717788
20.

Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.

Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.

Blood Cells Mol Dis. 2014 Sep;53(3):164-7. doi: 10.1016/j.bcmd.2014.04.006. Epub 2014 May 17.

PMID:
24846580

Supplemental Content

Support Center